Italian Sarcoma Group
Quick facts
Marketed products
- ADM · Oncology
ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death. - CYC · Oncology
CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation. - ETO · Oncology
ETO (etoposide) is a topoisomerase II inhibitor that prevents DNA religation, leading to DNA strand breaks and cell death. - IFO · Oncology
Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis. - VIN · Oncology
VIN (vinblastine) is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, thereby disrupting cell division and inducing apoptosis in rapidly dividing cells.
Phase 3 pipeline
- Intensified chemotherapy · Oncology
Intensified chemotherapy uses higher doses or more aggressive combinations of cytotoxic agents to maximize tumor cell kill in sarcoma patients.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Italian Sarcoma Group
What are Italian Sarcoma Group's marketed drugs?
Top marketed products include ADM, CYC, ETO, IFO, VIN.
What is Italian Sarcoma Group's pipeline?
Italian Sarcoma Group has 1 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include Intensified chemotherapy.